497 related articles for article (PubMed ID: 23436141)
1. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway.
Lucas K; Maes M
Mol Neurobiol; 2013 Aug; 48(1):190-204. PubMed ID: 23436141
[TBL] [Abstract][Full Text] [Related]
2. The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue.
Lucas K; Morris G; Anderson G; Maes M
CNS Neurol Disord Drug Targets; 2015; 14(7):838-54. PubMed ID: 25801843
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
4. Activation of Toll-like receptors by Burkholderia pseudomallei.
West TE; Ernst RK; Jansson-Hutson MJ; Skerrett SJ
BMC Immunol; 2008 Aug; 9():46. PubMed ID: 18691413
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.
Li J; Csakai A; Jin J; Zhang F; Yin H
ChemMedChem; 2016 Jan; 11(2):154-65. PubMed ID: 26136385
[TBL] [Abstract][Full Text] [Related]
6. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue.
Vitseva OI; Tanriverdi K; Tchkonia TT; Kirkland JL; McDonnell ME; Apovian CM; Freedman J; Gokce N
Obesity (Silver Spring); 2008 May; 16(5):932-7. PubMed ID: 18292749
[TBL] [Abstract][Full Text] [Related]
7. Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.
Romerio A; Peri F
Front Immunol; 2020; 11():1210. PubMed ID: 32765484
[TBL] [Abstract][Full Text] [Related]
8. Soyasaponin Bb inhibits the recruitment of toll-like receptor 4 (TLR4) into lipid rafts and its signaling pathway by suppressing the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent generation of reactive oxygen species.
Zhang Y; Chen F; Chen J; Huang S; Chen J; Huang J; Li N; Sun S; Chu X; Zha L
Mol Nutr Food Res; 2016 Jul; 60(7):1532-43. PubMed ID: 27005845
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide induced altered signaling pathways in various neurological disorders.
Singh S; Sahu K; Singh C; Singh A
Naunyn Schmiedebergs Arch Pharmacol; 2022 Mar; 395(3):285-294. PubMed ID: 34989812
[TBL] [Abstract][Full Text] [Related]
10. [Research progress of TLR4 signaling pathway and its targeted drugs].
Zhang J; Shang D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):657-662. PubMed ID: 34140078
[TBL] [Abstract][Full Text] [Related]
11. The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway.
Chen CY; Kao CL; Liu CM
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213077
[TBL] [Abstract][Full Text] [Related]
12. Insight Into TLR4-Mediated Immunomodulation in Normal Pregnancy and Related Disorders.
Firmal P; Shah VK; Chattopadhyay S
Front Immunol; 2020; 11():807. PubMed ID: 32508811
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression.
Ryan KA; Smith MF; Sanders MK; Ernst PB
Infect Immun; 2004 Apr; 72(4):2123-30. PubMed ID: 15039334
[TBL] [Abstract][Full Text] [Related]
14. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule.
Lysakova-Devine T; Keogh B; Harrington B; Nagpal K; Halle A; Golenbock DT; Monie T; Bowie AG
J Immunol; 2010 Oct; 185(7):4261-71. PubMed ID: 20802145
[TBL] [Abstract][Full Text] [Related]
15. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH
J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811
[TBL] [Abstract][Full Text] [Related]
16. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.
Erridge C; Kennedy S; Spickett CM; Webb DJ
J Biol Chem; 2008 Sep; 283(36):24748-59. PubMed ID: 18559343
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptors 2 and 4 mediate hyperglycemia induced macrovascular aortic endothelial cell inflammation and perturbation of the endothelial glycocalyx.
Pahwa R; Nallasamy P; Jialal I
J Diabetes Complications; 2016; 30(4):563-72. PubMed ID: 26908090
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.
Kim SY; Koo JE; Seo YJ; Tyagi N; Jeong E; Choi J; Lim KM; Park ZY; Lee JY
Br J Pharmacol; 2013 Apr; 168(8):1933-45. PubMed ID: 23231684
[TBL] [Abstract][Full Text] [Related]
19. The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation.
Molteni M; Gemma S; Rossetti C
Mediators Inflamm; 2016; 2016():6978936. PubMed ID: 27293318
[TBL] [Abstract][Full Text] [Related]
20. Saturated fatty acids trigger TLR4-mediated inflammatory response.
Rocha DM; Caldas AP; Oliveira LL; Bressan J; Hermsdorff HH
Atherosclerosis; 2016 Jan; 244():211-5. PubMed ID: 26687466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
